Arrowhead (ARWR) | Financial Analysis & Statements
Arrowhead Pharmaceuticals Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
264.0M
Operating Income
40.8M
15.46%
Net Income
28.2M
10.70%
EPS (Diluted)
$0.22
Balance Sheet Metrics
Total Assets
1.4B
Total Liabilities
881.9M
Shareholders Equity
503.4M
Debt to Equity
1.75
Cash Flow Metrics
Operating Cash Flow
41.4M
Free Cash Flow
11.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Arrowhead Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 829.4M | 3.6M | 240.7M | 243.2M | 138.3M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 607.2M | 505.9M | 353.2M | 297.3M | 206.3M |
| Selling, General & Administrative | 121.9M | 96.8M | 90.9M | 124.4M | 81.0M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 729.1M | 602.7M | 444.1M | 421.7M | 287.3M |
| Operating Income | 98.3M | -601.1M | -205.0M | -178.5M | -149.0M |
| Operating Margin % | 11.9% | -16,927.1% | -85.2% | -73.4% | -107.8% |
| Non-Operating Items | |||||
| Interest Income | 37.3M | 22.7M | 15.3M | 5.0M | 6.1M |
| Interest Expense | 89.4M | 32.4M | 18.3M | 0 | 0 |
| Other Non-Operating Income | 5.3M | -1.7M | 1.5M | 765.0K | 2.1M |
| Pre-tax Income | 51.5M | -612.5M | -206.5M | -172.7M | -140.8M |
| Income Tax | 21.4M | -2.8M | 2.8M | 3.8M | 2.0K |
| Effective Tax Rate % | 41.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | 30.1M | -609.7M | -209.3M | -176.5M | -140.8M |
| Net Margin % | 3.6% | -17,169.6% | -86.9% | -72.6% | -101.9% |
| Key Metrics | |||||
| EBITDA | 164.8M | -561.5M | -175.7M | -162.3M | -132.6M |
| EPS (Basic) | $-0.01 | $-5.00 | $-1.91 | $-1.63 | $-1.36 |
| EPS (Diluted) | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 |
| Basic Shares Outstanding | 133758000 | 119784000 | 107312000 | 105960000 | 103745000 |
| Diluted Shares Outstanding | 133758000 | 119784000 | 107312000 | 105960000 | 103745000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Arrowhead Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 88.7M | 102.7M | 110.9M | 108.0M | 184.4M |
| Short-term Investments | 830.7M | 578.3M | 292.7M | 268.4M | 183.4M |
| Accounts Receivable | 6.8M | - | 0 | 1.4M | 10.3M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 13.5M | 5.0M | 4.0M | 20.2M | 2.2M |
| Total Current Assets | 950.6M | 695.5M | 416.5M | 405.3M | 384.6M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 125.2M | 110.6M | 101.8M | 96.6M | 44.8M |
| Goodwill | 6.9M | 8.6M | 10.3M | 12.0M | 13.7M |
| Intangible Assets | 6.9M | 8.6M | 10.3M | 12.0M | 13.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.4M | 4.5M | 3.3M | 218.0K | 272.0K |
| Total Non-Current Assets | 434.7M | 444.3M | 349.1M | 286.6M | 325.6M |
| Total Assets | 1.4B | 1.1B | 765.6M | 691.9M | 710.1M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 17.7M | 11.4M | 35.9M | 2.9M | 9.5M |
| Short-term Debt | 47.3M | 6.3M | 10.6M | 2.8M | 2.2M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 10.8M | 432.0K | 435.0K | - | - |
| Total Current Liabilities | 195.5M | 103.2M | 105.5M | 138.8M | 146.5M |
| Non-Current Liabilities | |||||
| Long-term Debt | 319.0M | 504.2M | 104.6M | 78.8M | 23.3M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 686.4M | 845.6M | 372.9M | 134.8M | 154.8M |
| Total Liabilities | 881.9M | 948.7M | 478.4M | 273.6M | 301.3M |
| Equity | |||||
| Common Stock | 231.0K | 217.0K | 200.0K | 198.0K | 197.0K |
| Retained Earnings | -1.6B | -1.6B | -1.0B | -820.8M | -644.7M |
| Treasury Stock | 53.2M | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 503.4M | 191.1M | 287.2M | 418.3M | 408.8M |
| Key Metrics | |||||
| Total Debt | 366.3M | 510.6M | 115.2M | 81.6M | 25.5M |
| Working Capital | 755.2M | 592.3M | 311.0M | 266.4M | 238.1M |
Balance Sheet Composition
Arrowhead Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 30.1M | -609.7M | -209.3M | -176.5M | -140.8M |
| Depreciation & Amortization | 23.9M | 18.6M | 12.5M | 10.4M | 8.3M |
| Stock-Based Compensation | 63.4M | 74.0M | 78.1M | 120.9M | 76.7M |
| Working Capital Changes | -49.8M | -5.4M | -48.2M | -96.8M | 219.5M |
| Operating Cash Flow | 157.0M | -490.1M | -148.5M | -139.0M | 163.9M |
| Investing Activities | |||||
| Capital Expenditures | -22.7M | -141.5M | -176.7M | -52.8M | -23.6M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -796.3M | -720.9M | -246.1M | -223.4M | -240.7M |
| Investment Sales | 689.6M | 442.3M | 326.7M | 270.8M | 122.6M |
| Investing Cash Flow | -129.3M | -420.1M | -96.2M | -5.4M | -141.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 392.0M | 0 | 0 | - |
| Debt Repayment | -201.6M | - | - | - | 0 |
| Financing Cash Flow | 45.0M | 868.1M | 250.0M | 60.0M | 0 |
| Free Cash Flow | 156.9M | -604.3M | -330.6M | -188.9M | 147.7M |
| Net Change in Cash | 72.7M | -42.1M | 5.3M | -84.4M | 22.2M |
Cash Flow Trend
Arrowhead Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
46.50
Forward P/E
-16.48
Price to Book
17.98
Price to Sales
9.55
PEG Ratio
-0.40
Profitability Ratios
Profit Margin
18.54%
Operating Margin
15.46%
Return on Equity
75.50%
Return on Assets
14.35%
Financial Health
Current Ratio
3.38
Debt to Equity
124.07
Beta
1.27
Per Share Data
EPS (TTM)
$1.60
Book Value per Share
$4.14
Revenue per Share
$7.98
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ARWR | 10.4B | 46.50 | 17.98 | 75.50% | 18.54% | 124.07 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Alnylam | 41.9B | 132.73 | 52.09 | 73.28% | 8.45% | 376.19 |
| Insmed | 31.0B | -22.40 | 40.88 | -249.28% | -210.54% | 101.43 |
| Revolution Medicines | 28.6B | -22.73 | 16.24 | -58.07% | 0.00% | 26.19 |
Financial data is updated regularly. All figures are in the company's reporting currency.






